Literature DB >> 3582068

DNA ploidy and survival in breast cancer patients.

C J Cornelisse, C J van de Velde, R J Caspers, A J Moolenaar, J Hermans.   

Abstract

Flow cytometric DNA ploidy measurements using frozen or deparaffinized tumor specimens were performed on 565 primary breast cancers from patients treated in the period 1975-1984. Twenty-nine percent of the cases were diploid, 61% had a single aneuploid stemline, and 10% were multiploid. Aneuploid tumors more often had negative estrogen receptor values than diploid tumors, but no significant correlation was found between ploidy class and TNM stage. Patients with more than ten positive axillary lymph nodes had predominantly aneuploid tumors. Overall and distant relapse-free survival were higher for patients with diploid tumors and low-aneuploid tumors. Stratification of the patients according to degree of lymph node involvement, TNM stage, and menopausal stage showed that the prognostic effect of aneuploidy was apparent predominantly in patients with locally advanced disease. Postmenopausal node-positive patients with diploid tumors had a significantly better prognosis than those with aneuploid tumors, but this difference was not found for the comparable premenopausal group. Multivariate analysis with the Cox proportional hazards model indicated that ploidy is an additional, independent prognostic factor in postmenopausal patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582068     DOI: 10.1002/cyto.990080217

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  59 in total

1.  Significance of Flow Cytometric DNA Analysis from Freshly Aspirated Samples.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Flow cytometric analysis of the nuclear DNA content of hepatocellular carcinoma.

Authors:  H Ishizu
Journal:  Jpn J Surg       Date:  1989-11

3.  An Evaluation of DNA Polymerase alpha as a Prognostic Predictor in Early Breast Cancers Smaller than 2 cm.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

4.  Has adjuvant treatment of breast cancer had an unfair trial?

Authors:  I Mittra
Journal:  BMJ       Date:  1990-12-08

Review 5.  Aneuploidy as a prognostic factor in breast cancer.

Authors:  A von Rosen
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

7.  Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.

Authors:  Johanna Oltmann; Kerstin Heselmeyer-Haddad; Leanora S Hernandez; Rüdiger Meyer; Irianna Torres; Yue Hu; Natalie Doberstein; J Keith Killian; David Petersen; Yuelin Jack Zhu; Daniel C Edelman; Paul S Meltzer; Russell Schwartz; E Michael Gertz; Alejandro A Schäffer; Gert Auer; Jens K Habermann; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2018-01-09       Impact factor: 5.006

8.  DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases.

Authors:  G E Feichter; M Kaufmann; A Müller; D Haag; R Eckhardt; K Goerttler
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

9.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

10.  A retrospective study on the clinical and biological prediction of axillary lymph node metastasis in breast cancer.

Authors:  M Noguchi; N Ohta; M Thomas; H Kitagawa; M Earashi; I Miyazaki; Y Mizukami
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.